|Bid||89.02 x 1400|
|Ask||89.45 x 900|
|Day's Range||87.06 - 89.99|
|52 Week Range||16.12 - 105.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.64|
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) should know very soon if their coronavirus vaccine candidate BNT172b2 works. The two companies expect to be able to file for Emergency Use Authorization (EUA) with the Food and Drug Administration by the third week of November. How long will it take the FDA to make a decision?
Yahoo Finance’s Alexis Christoforous and Brian Sozzi discuss the latest news on the COVID-19 vaccine front with Yahoo Medical Contributor, Dr. Dara Kass.
Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) have been hot stocks this year. At the same time, as rumors swirl regarding the conclusions of each company's phase 3 clinical trials, investors everywhere are hunting for the best competitors in the rapidly expanding coronavirus market. Given that both Moderna and BioNTech have exhibited lightning-fast vaccine development, it's anyone's guess as to which has a better chance of winning the coronavirus vaccine race.